← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (20)Treatment guideline (4)Phase 3 study (27)Randomized trial (14)Systematic review (14)Clinical trial (677)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Commentary or editorialiAn expert's opinion or commentary, not new research. Two-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia: A Small Uncontrolled Trial. (2023/12/01) ♡
• Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients. (2023/12/01) ♡
• ASPARTATE AMINOTRANSFERASE AND GAMMA-GLUTAMYL TRANSFERASE: INTRIGUING CLINICAL BIOMARKERS IN DISCRIMINATION OF HEPATIC LESION BETWEEN HEPATITIS C INFECTED PATIENTS AND HEALTHY CONTROLS. (2023/12/01) ♡
• Community-based actions in consulates: a new paradigm for opportunities for systematic integration in Chagas disease detection. (2023/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older. (2023/12/01) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. (2023/12/01) ♡
• Identification and characterization of Sofosbuvir-resistant mutations of hepatitis C virus genotype 3a replicon. (2023/12/01) ♡
• A multicentric and nationwide predictive study role of T cell sub-population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients. (2023/12/01) ♡
• Suppressor of Cytokine Signaling-3 Gene Polymorphisms and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients in Egypt. (2023/12/01) ♡
• Generalized cost-effectiveness analysis to assess treatment value in hepatitis C. (2023/12/01) ♡
• Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals. (2023/12/01) ♡
• Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure. (2023/12/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Outcomes of direct-acting antivirals in patients with HCV decompensated cirrhosis: a systematic review and meta-analysis. (2023/11/29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea. (2023/11/27) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Editorial: Metabolomics in chronic hepatitis C: Decoding fibrosis grading and underlying pathways. (2023/11/27) ♡
• Metabolomics in chronic hepatitis C: Decoding fibrosis grading and underlying pathways. (2023/11/27) ♡
• Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data. (2023/11/25) ♡
• Low Hepatitis C Virus Prevalence among Men Who Have Sex with Men Attending Public Health Services in The Netherlands. (2023/11/25) ♡
• SARS-CoV-2 genomics and impact on clinical care for COVID-19. (2023/11/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life. (2023/11/18) ♡
• Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis. (2023/11/17) ♡
• Cytokine profile and viral diversity in the early seronegative stage of community-acquired hepatitis C virus (HCV) infection. (2023/11/16) ♡
• Public healthcare system utilization for chronic hepatitis C infection in Vietnam. (2023/11/16) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Suppression of Innate Immunity by the Hepatitis C Virus (HCV): Revisiting the Specificity of Host-Virus Interactive Pathways. (2023/11/08) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. HCV and HCC Tango-Deciphering the Intricate Dance of Disease: A Review Article. (2023/11/07) ♡
• Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study. (2023/11/06) ♡
• Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells. (2023/11/01) ♡
• Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals. (2023/11/01) ♡
• Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital. (2023/11/01) ♡
• TLR3 Gene Polymorphism in HCV Infection in the Kazakh Population of Western Kazakhstan. (2023/11/01) ♡
• Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis. (2023/11/01) ♡
• PNI, NLR and PLR combined detection prognosis of patients with chronic hepatitis C-associated cirrhosis complicated by T2DM. (2023/10/31) ♡
• Direct-Acting Antiviral Drug Modulates the Mitochondrial Biogenesis in Different Tissues of Young Female Rats. (2023/10/31) ♡
• Country-Wide HCV Elimination Strategies Need to Reach Older Patients in the General Population: The Italian Experience. (2023/10/31) ♡
• Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication. (2023/10/30) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence. (2023/10/28) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Triple Threat: Triple Pathogen Endocarditis. (2023/10/28) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Acute-on-chronic liver failure induced by antiviral therapy for chronic hepatitis C: A case report. (2023/10/26) ♡
• [Assessment of body mass index in patients with chronic hepatitis C who received an effective antiviral therapy]. (2023/10/11) ♡
• Chronic viral hepatitis accelerates lung function decline in smokers. (2023/10/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. (2023/10/01) ♡
• Impact of direct antiviral agents for hepatitis C virus -induced liver diseases on registration, waiting list and liver transplant activity in France. (2023/10/01) ♡
• In HIV-Infected Immunological Non-Responders, Hepatitis C Virus Eradication Contributes to Incomplete Normalization of Systemic Inflammation Indexes, but Does Not Lead to Rapid CD4+ T-Cell Count Recovery. (2023/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C virus-positive donors in HCV-negative recipients in liver transplantation: Is it possible in Mexico? (2023/10/01) ♡
• Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals. (2023/10/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients. (2023/10/01) ♡
• Predictive Potential Of Il28b Gene In Hcv Patients, Resistant To Daclatasvir And Sofosbuvir In KPK Population. (2023/10/01) ♡
• Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. (2023/09/29) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Risk of Hepatitis C Virus Transmission through Acupuncture: A Systematic Review and Meta-Analysis. (2023/09/25) ♡
• Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir. (2023/09/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.